DelveInsight’s “Glioblastoma Multiforme Market Insight, Epidemiology, and Market Forecast–2034” report delivers an in-depth understanding of GBM, historical and forecasted epidemiology as well as the GBM market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

 

Discover Key Insights into the Glioblastoma Multiforme Market with DelveInsight’s In-Depth Report @ Glioblastoma Multiforme Market Size

 

Key Takeaways from the Glioblastoma Multiforme Market Report

• Among the 7MM, the US accounted for approximately 41%, EU4 and the UK for 51%, and Japan for 8% of the total incident cases of GBM in 2023.
• In the EU4 and the UK, in 2023, the maximum number of incident cases according to the histological classification was for glioblastoma with approximately 17,550 cases while the lowest incident cases were of giant cell glioblastoma type with approximately 150 cases, which are expected to increase by 2034.
• In Japan, in 2023, the highest number of cases in the targeted therapy pool was for first-line treatments, with 2,690 cases, followed by second-line and above treatments with 1,365 cases.
• As per the DelveInsight estimates, it has been found that the primary site of GBM included maximum cases at the parietal site, while the minimum number of cases were found in unknown and other sites. This trend is evident across all the 7MM countries for the study period.
• The leading Glioblastoma Multiforme Companies such as Genentech, Merck, Daiichi Sankyo, VBL Therapeutics, Diffusion Pharmaceuticals Bayer, MedImmune, DNAtrix, Chimerix, Karyopharm Therapeutics, VBI Vaccines, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, Kintara Therapeutics, Laminar Pharmaceuticals, Immunomic Therapeutics, Inovio Pharmaceuticals, Treovir, Istari Oncology, and others.
• Promising Glioblastoma Multiforme Pipeline Therapies such as Regorafenib, ONC201, AV-GBM-1, Enzastaurin (DB-102), DCVax-L, LAM561 (2-OHOA), Tasadenoturev (DNX-2401), ITI-1000 (pp65 DC Vaccine), SurVaxM, Berubicin, GLIOVAC (Sitoiganap), Lerapolturev + Pembrolizumab, VAL-083 (dianhydrogalactitol), MDNA55, Paxalisib (GDC-0084), Temferon, EO2401, INO-5401 + INO-9012 + LIBTAYO (cemiplimab), Delytact (Teserpaturev/DS-1647), TAFINLAR + MEKINIST, VBI-1901, and others.

 

Stay ahead in the Glioblastoma Multiforme Therapeutics Market with DelveInsight’s Strategic Report @ Glioblastoma Multiforme Market Outlook

 

Glioblastoma Multiforme Epidemiology Segmentation in the 7MM

• Total Glioblastoma Multiforme Incident Population
• Glioblastoma Multiforme Gender-specific Incidence Cases
• Glioblastoma Multiforme Type-specific Incidence Cases
• Glioblastoma Multiforme Incident Cases based on Primary Site
• Glioblastoma Multiforme Age-specific Incidence Cases
• Incident Cases Based on Histologic Classification of Glioblastoma Multiforme Tumor
• Unmethylation of the MGMT Gene Promoter Cases,
• BRAF V600E Mutation Cases
• Line-wise Treated Pool

 

Download the report to understand which factors are driving Glioblastoma Multiforme epidemiology trends @ Glioblastoma Multiforme Prevalence

 

Glioblastoma Multiforme Marketed Drugs

 

• AVASTIN (bevacizumab): Roche (Genentech)

AVASTIN is a recombinant humanized monoclonal IgG1 antibody, which acts as an angiogenesis inhibitor by blocking its target, vascular endothelial growth factor (VEGF). It binds to the VEGF with its receptors VEGFR-1 and VEGFR-2, which are present on the surface of endothelial cells. This helps reduce VEGF activity and regress the vascularization of tumors, normalizing the tumor vasculature and inhibiting the formation of new tumor vasculature, thereby preventing tumor growth. VEGF is a chemical signal that stimulates angiogenesis in various diseases, especially cancer.

 

• TEMODAR/TEMODAL (temozolomide): Merck

The active pharmaceutical ingredient in TEMODAR/TEMODAL is an imidazotetrazine derivative of the alkylating agent dacarbazine. It is used for treating several brain cancer forms, e.g., as a second-line treatment for astrocytoma and a first-line treatment for GBM. The therapeutic benefit of TEMODAR is its ability to alkylate/methylate DNA. This alkylation/methylation destroys the DNA and triggers the death of the tumor cells. TEMODAR targets tumoral tissues selectively; it has an anti-neoplastic effect; it has minimum influence on adjacent brain tissues; it has no severe systemic toxicity; and it is eliminated rapidly.

 

Glioblastoma Multiforme Emerging Drugs

 

• DCVax-L: Northwest Biotherapeutics and Advent BioServices

DCVax-L is a fully personalized immune therapy made from a patient’s immune cells (dendritic cells) and antigens (biomarkers) from a sample of the patient’s tumor. DCVax-L is expected to be used for any solid tumor cancers in situations where the patient has their tumor surgically removed as part of standard care. DCVax -L is administered to the patient through a simple intradermal injection in the upper arm, similar to a flu shot. The dendritic cells then convey the tumor biomarker information to the rest of the immune system agents (T cells, B cells, and others) as “marching orders,” and the immune system agents fan out through the body, searching for anything with these biomarkers and attacking it.

 

• TVI-Brain-1: TVAX Biomedical

TVI-Brain-1 is a patented vaccine-enhanced adoptive T-cell therapy (VACT) of TVAX Biomedical containing attenuated autologous cancer cells and activated autologous blood-derived T cells, developed through TVAX’s immunotherapeutic cancer treatment platform. TVAX Immunotherapy is a proprietary method for treating cancer using many activated, genetically unique cancer-specific killer T cells. This vaccination generates an immune response in the patient, producing many cancer-specific T cells. The activated killer T cells trigger the body’s immune system to destroy cancer cells, including cancer stem cells.

 

Get In-Depth Knowledge on Glioblastoma Multiforme Market Trends and Forecasts with DelveInsight @ Glioblastoma Multiforme Treatment Market

 

Glioblastoma Multiforme Market Outlook

Glioblastoma is a malignant brain tumor that develops from a specific type of brain cell called an astrocyte. These cells nourish neurons (nerve cells of the brain) and form scar tissue that helps repair brain damage in response to injury. Glioblastomas are often very aggressive and grow into surrounding brain tissue. Unfortunately, there is no cure for glioblastoma. Glioblastoma treatment is quite challenging as some cells may respond well to certain therapies while others may not be affected at all. Because of this, the treatment plan for glioblastoma may combine several approaches. The treatment often comprises a combination of several therapies, including surgery, chemotherapy, radiation, or stereotactic radiosurgery, followed by additional/adjuvant treatments, such as chemotherapy or radiation therapy, after surgery.

 

Scope of the Glioblastoma Multiforme Market Report

• Coverage- 7MM
• Glioblastoma Multiforme Companies- Genentech, Merck, Daiichi Sankyo, VBL Therapeutics, Diffusion Pharmaceuticals Bayer, MedImmune, DNAtrix, Chimerix, Karyopharm Therapeutics, VBI Vaccines, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, Kintara Therapeutics, Laminar Pharmaceuticals, Immunomic Therapeutics, Inovio Pharmaceuticals, Treovir, Istari Oncology, and others.
• Glioblastoma Multiforme Pipeline Therapies- Regorafenib, ONC201, AV-GBM-1, Enzastaurin (DB-102), DCVax-L, LAM561 (2-OHOA), Tasadenoturev (DNX-2401), ITI-1000 (pp65 DC Vaccine), SurVaxM, Berubicin, GLIOVAC (Sitoiganap), Lerapolturev + Pembrolizumab, VAL-083 (dianhydrogalactitol), MDNA55, Paxalisib (GDC-0084), Temferon, EO2401, INO-5401 + INO-9012 + LIBTAYO (cemiplimab), Delytact (Teserpaturev/DS-1647), TAFINLAR + MEKINIST, VBI-1901, and others.
• Glioblastoma Multiforme Market Dynamics: Glioblastoma Multiforme Market Drivers and Barriers

 

Unlock Strategic Insights with DelveInsight’s Comprehensive Glioblastoma Multiforme Market Report @ Glioblastoma Multiforme Market Drivers and Barriers

 

Table of Content

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

5. Epidemiology and Market Forecast Methodology

6. GBM Market Overview at a Glance

7. Disease Background and Overview: GBM

8. Treatment and Management

9. Epidemiology and Patient Population

10. Patient Journey

11. Key Endpoints

12. Marketed Drugs

13. Emerging Drugs

14. GBM: Seven Major Market Analysis

15. Unmet Needs

16. SWOT Analysis

17. KOL Views

18. Market Access and Reimbursement

18.4. Market Access and Reimbursement of GBM

19. Appendix

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services